ixt-m200
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 3, 2018 (NCT03336866)
Timeline
Indications
Mechanism of action
- methamphetamineINHIBITOR
methamphetamine inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05034874 | Phase 2 | Apr 1, 2022 | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA) |
| NCT05027451 | Phase 1 | Oct 25, 2021 | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA) |
| NCT04715230 | Phase 2 | Jun 30, 2021 | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA) |
| NCT03336866 | Phase 1/Phase 2 (Phase 2) | May 3, 2018 | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA), Pharmaceutical Research Associates, Inc. (PRA) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InterveXion Therapeutics, LLC | For profit | 4 | 4 | 2 | 2018 |
| National Institute on Drug Abuse (NIDA) | Government | 4 | 0 | 2 | 2018 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1